Jason Amello - 20 Jan 2026 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: TCRX
Reported as of: 20 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jan 2026, 17:52:24 UTC
Prior SEC filing: 11 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Zoran Zdraveski, Attorney-in-Fact

Key filing fact

Jason Amello filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 22 Jan 2026.

Key facts

This page summarizes Jason Amello's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jan 2026, 17:52.

Change

Previous filing in this sequence was filed on 11 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001451805 Primary reporting owner

Amello Jason

Relationship: Chief Financial Officer
Address: C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM
Signature: /s/ Zoran Zdraveski, Attorney-in-Fact
Signature date: 22 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TCRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +350,000
Change %
Price: $0.000000
Shares after: 350,000
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 350,000
Exercise price: $1.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.